The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Am J Obstet Gynecol
; 218(6): 563-572.e1, 2018 06.
Article
em En
| MEDLINE
| ID: mdl-29274830
ABSTRACT
Uterine fibroids are common in women of reproductive age and can have a significant impact on quality of life and fertility. Although a number of international obstetrics/gynecology societies have issued evidence-based clinical practice guidelines for the management of symptomatic uterine fibroids, many of these guidelines do not yet reflect the most recent clinical evidence and approved indication for one of the key medical management options the selective progesterone receptor modulator class. This article aims to share the clinical experience gained with selective progesterone receptor modulators in Europe and Canada by reviewing the historical development of selective progesterone receptor modulators, current best practices for selective progesterone receptor modulator use based on available data, and potential future uses for selective progesterone receptor modulators in uterine fibroids and other gynecologic conditions.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Uterinas
/
Receptores de Progesterona
/
Anticoncepcionais Femininos
/
Leiomioma
/
Norpregnadienos
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Am J Obstet Gynecol
Ano de publicação:
2018
Tipo de documento:
Article